Announcement

Collapse
No announcement yet.

UK - Gov: COVID-19 variant Delta trend & Omicron becoming dominant, and now Omicron 2.....

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • #91

    Click image for larger version

Name:	ukcovid323.png
Views:	40
Size:	94.8 KB
ID:	943891

    Overall summary of the respiratory viruses in circulation within the UK

    Comment


    • #92
      bump this

      Comment


      • #93
        Click image for larger version

Name:	ukcovid324.png
Views:	35
Size:	88.8 KB
ID:	944060

        Overall summary of the respiratory viruses in circulation within the UK


        Comment


        • #94

          COVID-19 vaccine surveillance report

          Week 12
          24 March 2022

          UK Health Security Agency

          Executive summary
          Four coronavirus (COVID-19) vaccines have now been approved for use in the UK. Rigorous clinical trials have been undertaken to understand the immune response, safety profile and efficacy of these vaccines as part of the regulatory process. Ongoing monitoring of the vaccines as they are rolled out in the population is important to continually ensure that clinical and public health guidance on the vaccination programme is built upon the best available evidence.

          UK Health Security Agency (UKHSA), formerly Public Health England (PHE), works closely with the Medicines and Healthcare Regulatory Agency (MHRA), NHS England, and other government, devolved administration and academic partners to monitor the COVID-19 vaccination programme. Details of the vaccine surveillance strategy are set on the pageCOVID-19: vaccine surveillance strategy (1). As with all vaccines, the safety of COVID-19vaccines is continuously being monitored by the MHRA. They conclude that overall, the benefits of COVID-19 vaccines outweigh any potential risks (2).

          Vaccine effectiveness
          Several studies of vaccine effectiveness have been conducted in the UK against different COVID-19 variants. Vaccine effectiveness against symptomatic disease with the Omicron variant is substantially lower than against the Delta variant, with rapid waning. However, protection against hospitalisation remains high, particularly after 3 doses.

          Population impact
          The impact of the vaccination programme on the population is assessed by taking into account vaccine coverage, evidence on vaccine effectiveness and the latest COVID-19 disease surveillance indicators.

          Vaccine coverage tells us about the proportion of the population that have received one, 2 and 3 doses of COVID-19 vaccines. By 20 March 2022, the overall vaccine uptake in England for dose 1 was 69.5% and for dose 2 was 65.2%. Overall vaccine uptake in England in people with at least 3 doses was 50.8%. In line with the programme rollout, coverage is highest in the oldest age groups.

          We present data on COVID-19 cases, hospitalisations and deaths by vaccination status. This raw data should not be used to estimate vaccine effectiveness as the data does not take into account inherent biases present such as differences in risk, behaviour and testing in the vaccinated and unvaccinated populations. Vaccine effectiveness is measured in other ways as detailed in the Vaccine effectiveness section below. ...


          Comment


          • #95
            bump this

            Comment


            • #96

              Click image for larger version

Name:	ukcovid040422.png
Views:	29
Size:	93.6 KB
ID:	945120

              Overall summary of the respiratory viruses in circulation within the UK

              Comment


              • #97
                bump this

                Comment


                • #98

                  Click image for larger version

Name:	ukcovid415.JPG
Views:	24
Size:	120.4 KB
ID:	946100 Click image for larger version

Name:	ukcovid415.JPG
Views:	25
Size:	120.4 KB
ID:	946101

                  Overall summary of the respiratory viruses in circulation within the UK

                  Comment

                  Working...
                  X